Trastuzumab deruxtecan (Enhertu) is an antibody-drug conjugate approved to treat people with metastatic, HER2-postive, hormone receptor-negative breast cancer that has grown after at least two past treatments.
The Food and Drug Administration approved trastuzumab deruxtecan to treat metastatic, HER2-positive breast cancer that has grown after at least two past lines of HER2-targeted treatment for metastatic breast cancer. These include common therapies like trastuzumab (Herceptin or biosimilar) and ado-trastuzumab emtansine (Kadcyla).
Trastuzumab deruxtecan is given by vein once every 3 weeks at your doctor’s office or infusion center. Your care team determines the dose by your weight, and you’ll get it over about 30 minutes (90 minutes for your first infusion). Treatment can continue until the cancer grows or spreads to other parts of the body or you and your doctor decide to stop because of side effects.
- nausea and vomiting
- low white blood cell counts
- hair loss
- constipation or diarrhea
- low red blood cell counts
In rare cases, some people developed a very serious lung condition called interstitial lung disease. On scans, this disease looks like scarring or inflammation of the lungs. This condition can be fatal. You should report any lung problems you have while taking this medicine to your doctor immediately, including
- trouble breathing
- shortness of breath
Like other HER2-targeting medicines, trastuzumab deruxtecan can also affect your heart function. Your doctor will watch for problems in your heart, but let them know if you have symptoms such as sudden weight gain, swelling, dizziness, or if you faint.
Trastuzumab deruxtecan may be dangerous to a fetus if taken during or before a pregnancy. You should not take it if you are pregnant or breastfeeding, and you should take steps to avoid getting pregnant while on trastuzumab deruxtecan. Men taking trastuzumab deruxtecan should also take steps to avoid getting their partner pregnant.